DK2411397T3 - Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 - Google Patents
Isothiazol-pyrimidindionderivater som modulatorer af TRPA1Info
- Publication number
- DK2411397T3 DK2411397T3 DK10716049.1T DK10716049T DK2411397T3 DK 2411397 T3 DK2411397 T3 DK 2411397T3 DK 10716049 T DK10716049 T DK 10716049T DK 2411397 T3 DK2411397 T3 DK 2411397T3
- Authority
- DK
- Denmark
- Prior art keywords
- trpa1
- isothiazole
- modulators
- pyrimidinedione derivatives
- pyrimidinedione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 | |
| PCT/IB2010/000834 WO2010109328A1 (en) | 2009-03-23 | 2010-03-22 | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2411397T3 true DK2411397T3 (da) | 2013-08-05 |
Family
ID=42236291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10716049.1T DK2411397T3 (da) | 2009-03-23 | 2010-03-22 | Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8575178B2 (da) |
| EP (1) | EP2411397B1 (da) |
| JP (1) | JP2012521405A (da) |
| KR (1) | KR20120001746A (da) |
| CN (1) | CN102395592A (da) |
| AP (1) | AP2011005888A0 (da) |
| AU (1) | AU2010227224A1 (da) |
| BR (1) | BRPI1009372A2 (da) |
| CA (1) | CA2756534A1 (da) |
| DK (1) | DK2411397T3 (da) |
| EA (1) | EA201190191A1 (da) |
| ES (1) | ES2424340T3 (da) |
| HK (1) | HK1166081A1 (da) |
| IL (1) | IL215179A0 (da) |
| MX (1) | MX2011009821A (da) |
| PE (1) | PE20120764A1 (da) |
| PL (1) | PL2411397T3 (da) |
| PT (1) | PT2411397E (da) |
| SG (2) | SG184766A1 (da) |
| SI (1) | SI2411397T1 (da) |
| UA (1) | UA107342C2 (da) |
| WO (1) | WO2010109328A1 (da) |
| ZA (1) | ZA201107646B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012521406A (ja) | 2009-03-23 | 2012-09-13 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｒｐａ１調節因子としてのフロピリミジンジオン誘導体 |
| PE20120774A1 (es) | 2009-03-23 | 2012-06-27 | Glenmark Pharmaceuticals Sa | COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1 |
| AU2011346763B2 (en) * | 2010-12-20 | 2016-01-07 | Glenmark Pharmaceuticals S.A. | 2-amino-4-arylthiazole compounds as TRPA1 antagonists |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| RU2014100744A (ru) | 2011-06-13 | 2015-07-20 | Гленмарк Фармасьютикалс С.А. | Лечение респираторных нарушений с помощью trpa1 антагонистов |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| US20140107113A1 (en) | 2011-06-22 | 2014-04-17 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist |
| US20140148423A1 (en) | 2011-07-25 | 2014-05-29 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| TWI640519B (zh) * | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Ｈｅｃ１活性調控因子及其調節方法 |
| US20140364445A1 (en) * | 2011-12-05 | 2014-12-11 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| SG11201408093PA (en) | 2012-06-08 | 2015-01-29 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
| KR102164756B1 (ko) | 2012-10-01 | 2020-10-14 | 오리온 코포레이션 | N-프로프-2-이닐 카복스아미드 유도체 및 trpa1 길항제로서의 이의 용도 |
| CA2884767A1 (en) | 2012-11-14 | 2014-05-22 | Stephan Bachmann | Imidazopyridine derivatives |
| EP3010489A1 (en) | 2013-06-20 | 2016-04-27 | Glenmark Pharmaceuticals S.A. | Nanoparticulate formulation comprising a trpa1 antagonist |
| WO2015056094A2 (en) | 2013-10-15 | 2015-04-23 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
| WO2015155306A1 (en) * | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
| US20190175599A1 (en) | 2014-09-16 | 2019-06-13 | Glemark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| WO2018233648A1 (zh) * | 2017-06-21 | 2018-12-27 | 南京明德新药研发股份有限公司 | 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物 |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) * | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| WO2004055054A1 (en) | 2002-12-18 | 2004-07-01 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| WO2005077959A1 (en) * | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
| US20090062258A1 (en) | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| EP1962855B1 (en) * | 2005-12-22 | 2013-08-21 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| SI3184527T1 (sl) * | 2007-06-22 | 2020-03-31 | Eli Lilly And Company | Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
-
2010
- 2010-03-22 SG SG2012069464A patent/SG184766A1/en unknown
- 2010-03-22 DK DK10716049.1T patent/DK2411397T3/da active
- 2010-03-22 US US13/257,241 patent/US8575178B2/en not_active Expired - Fee Related
- 2010-03-22 ES ES10716049T patent/ES2424340T3/es active Active
- 2010-03-22 EP EP10716049.1A patent/EP2411397B1/en not_active Not-in-force
- 2010-03-22 SG SG2011066495A patent/SG174403A1/en unknown
- 2010-03-22 EA EA201190191A patent/EA201190191A1/ru unknown
- 2010-03-22 PE PE2011001703A patent/PE20120764A1/es not_active Application Discontinuation
- 2010-03-22 AU AU2010227224A patent/AU2010227224A1/en not_active Abandoned
- 2010-03-22 JP JP2012501411A patent/JP2012521405A/ja not_active Withdrawn
- 2010-03-22 PT PT107160491T patent/PT2411397E/pt unknown
- 2010-03-22 SI SI201030232T patent/SI2411397T1/sl unknown
- 2010-03-22 CN CN2010800168801A patent/CN102395592A/zh active Pending
- 2010-03-22 CA CA2756534A patent/CA2756534A1/en not_active Abandoned
- 2010-03-22 PL PL10716049T patent/PL2411397T3/pl unknown
- 2010-03-22 KR KR1020117023383A patent/KR20120001746A/ko not_active Application Discontinuation
- 2010-03-22 MX MX2011009821A patent/MX2011009821A/es unknown
- 2010-03-22 BR BRPI1009372A patent/BRPI1009372A2/pt not_active IP Right Cessation
- 2010-03-22 WO PCT/IB2010/000834 patent/WO2010109328A1/en active Application Filing
- 2010-03-22 AP AP2011005888A patent/AP2011005888A0/xx unknown
- 2010-03-23 UA UAA201111149A patent/UA107342C2/ru unknown
-
2011
- 2011-09-15 IL IL215179A patent/IL215179A0/en unknown
- 2011-10-19 ZA ZA2011/07646A patent/ZA201107646B/en unknown
-
2012
- 2012-07-11 HK HK12106835.2A patent/HK1166081A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL215179A0 (en) | 2011-12-29 |
| AU2010227224A1 (en) | 2011-09-29 |
| PE20120764A1 (es) | 2012-06-27 |
| AP2011005888A0 (en) | 2011-10-31 |
| ZA201107646B (en) | 2012-06-25 |
| EA201190191A1 (ru) | 2012-11-30 |
| CN102395592A (zh) | 2012-03-28 |
| CA2756534A1 (en) | 2010-09-30 |
| US20120010223A1 (en) | 2012-01-12 |
| SI2411397T1 (sl) | 2013-07-31 |
| EP2411397A1 (en) | 2012-02-01 |
| UA107342C2 (en) | 2014-12-25 |
| WO2010109328A1 (en) | 2010-09-30 |
| US8575178B2 (en) | 2013-11-05 |
| ES2424340T3 (es) | 2013-10-01 |
| MX2011009821A (es) | 2012-01-25 |
| PL2411397T3 (pl) | 2013-10-31 |
| KR20120001746A (ko) | 2012-01-04 |
| PT2411397E (pt) | 2013-06-06 |
| SG184766A1 (en) | 2012-10-30 |
| AU2010227224A2 (en) | 2011-10-27 |
| SG174403A1 (en) | 2011-10-28 |
| BRPI1009372A2 (pt) | 2016-05-31 |
| HK1166081A1 (en) | 2012-10-19 |
| JP2012521405A (ja) | 2012-09-13 |
| EP2411397B1 (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2411397T3 (da) | Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 | |
| DK2411396T3 (da) | Thienopyrimidindionderivater som modulatorer af TRPA1 | |
| DK2411393T3 (da) | Kondenserede pyrimidin-dionderivater som TRPA1-modulatorer | |
| DK3124483T3 (da) | Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer | |
| DK2300465T3 (da) | Imidazopyridinderivater som hæmmere af receptortyrosinkinaser | |
| DK3235812T3 (da) | Deutererede derivater af ivacaftor | |
| DK2475657T3 (da) | 5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira | |
| DK3354657T3 (da) | Fremgangsmåde til fremstilling af planteafledte proteiner | |
| DK2310437T3 (da) | Fremgangsmåde til kontinuerlig fremstilling af polyestere | |
| DK2567524T3 (da) | Reduktion af protokolspild | |
| DK2646444T3 (da) | Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer | |
| BRPI1006128A2 (pt) | derivados de sulfonamida | |
| DK3156056T3 (da) | Farmaceutiske sammensætninger der består af sorbitanestere | |
| DK2526425T3 (da) | Fremgangsmåde til diagnosticering af endometriel receptivitet | |
| DK2603232T3 (da) | Stabile formuleringer af linaclotid | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener | |
| DK2405972T3 (da) | Anvendelse af rosuvastatin lactoler som medikamenter | |
| DK2260873T3 (da) | Pcylering af proteiner | |
| DK2408446T3 (da) | Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon | |
| DK2421537T3 (da) | Pyrazolylaminopyridiner som inhibitorer af FAK | |
| DK2459129T3 (da) | Forbedringer af karstøtteanordninger | |
| SMT201600076B (it) | Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo | |
| DK3070091T3 (da) | Benzodioxolderivater som phosphodiesterasehæmmere | |
| BR112012005371A2 (pt) | desmontagem de componentes interligados |